Efficient generation of constrained block allocation sequences

Statistics in Medicine

Volumn 27, Issue 9, 2008, Pages 1421-1428

  Salama, Ibrahim ^a   Ivanova, Anastasia ^b   Qaqish, Bahjat ^b  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b IL   (United States)

Author keywords

Constrained permuted block design; Maximal procedure; Restricted randomization; Selection bias

Indexed keywords

CARBOPLATIN; CETUXIMAB; PACLITAXEL;

ADVANCED CANCER; ALGORITHM; ARTICLE; BREAST CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; PROBABILITY; RANDOMIZATION; SYSTEMATIC ERROR;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); BIOMETRY; BREAST NEOPLASMS; CARBOPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MODELS, STATISTICAL; PACLITAXEL; PATIENT SELECTION; RANDOM ALLOCATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 42149124982     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3014     Document Type: Article

References (8)

1. Blackwell D, Hodges JL. Design for the control of selection bias. Annals of Mathematical Statistics 1957; 28:449-460.
2. Rosenberger W, Lachin JM. Randomization in Clinical Trials: Theory and Practice. Wiley: New York, 2001.
3. Matts JP, McHugh RB. Conditional Markov chain design for accrual clinical trials. Biometrical Journal 1983; 25:563-577.
4. Berger VW, Ivanova A, Knoll M. Minimizing predictability while retaining balance trough the use of less restrictive randomization procedures. Statistics in Medicine 2003; 22:3017-3028.
5. Berger VW. Selection Bias and Covariate Imbalances in Randomized Clinical Trials. Wiley: Chichester, 2005.
6. Youden WJ. Inadmissible random assignments. Technometrics 1964; 6:103-104.
7. Youden WJ. Randomization, experimentation. Technometrics 1972; 14:13-22.
8. Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Meras A, Tynan M, Beaumont J, Peterman AH, Niell HB. A randomized phase II trial comparing every-3-week carboplatin/paclitaxel with every-3-week carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Annals of Oncology 2006; 17:104-109.